Skip to content

Renal Artery Contrast-Free Trial

Comparison of Non-contrast Renal Artery Magnetic Resonance Angiography With Contrast-enhanced CT Angiography

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01576835
Acronym
REACT
Enrollment
75
Registered
2012-04-13
Start date
2012-02-29
Completion date
2012-12-31
Last updated
2015-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Kidney Diseases, Renal Artery Stenosis

Keywords

Non-contrast

Brief summary

This study will compare the results of a clinically ordered abdominal CT angiography to a research non-contrast MR angiogram (MRA). CTA is a gold-standard for identifying blockages in the kidney arteries or other blood vessel problems. CTA requires radiation and contrast to obtain useful images. Conversely, the MR abdomen technique being used for the study uses no radiation or contrast and is felt to be a safer option for individuals who have kidney problems. there is benefit to establishing non-contrast MRA as a clinically accurate test.

Detailed description

REACT is a prospective, minimal-risk, and multi-center international trial. The purpose of the study is to evaluate the safety and efficacy of non-contrast magnetic resonance angiography (MRA) for the diagnosis of renal artery stenosis (RAS). The current gold standards for diagnosing RAS are non-invasive 3D angiography with contrast-enhanced CTA/MRA or invasive X-ray angiography. All of these techniques require the use of an intravenous injection of either iodinated contrast material or gadolinium based agents. Iodinated contrast agents are contraindicated in patients with renal dysfunction and have increased risk of allergic reaction. Contrast-enhanced magnetic resonance angiography (MRA) with gadolinium has fewer risks associated with it, however, is currently contraindicated in patients with severe renal insufficiency because of concerns about developing a rare but often fatal condition termed nephrogenic systemic fibrosis (NSF). Non-contrast MRA techniques are felt to provide an avenue for safer, effective vascular imaging in patients both with and without kidney dysfunction. In this trial we propose to validate the contrast-free MRA technique, T-SLIP (time-spatial labeling inversion pulse), for diagnosing RAS. This study will compare T-SLIP to the reference standard of contrast-enhanced CTA and is designed to test its efficacy, reproducibility, reliability, and safety.

Interventions

None listed

Sponsors

Toshiba America Medical Systems, Inc.
CollaboratorINDUSTRY
Central Coast Cardiovascular Research
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* The abdominal CTA evaluation form has been completed and confirmed to fit criteria for study enrollment * The research MRA will be completed within 3 months of abdominal CTA * Subject signed and dated the informed consent form * Subject agrees to a research abdominal MRA * Subject is able to follow breathing and scanning instructions * Subject is at least 18 years of age

Exclusion criteria

* Subject has had a significant change in clinical condition between the time of abdominal CTA and abdominal MRA (e.g. worsening renal function, renal vascular intervention) * Subject has renal stents, or other known material that may affect MR image quality * Subject has a contraindication to an MRI * Subject had intravenous gadolinium media within the previous 24 hours * Subject has a baseline heart rate \>90 beats per minute or respiratory rate \>25 breaths/minute

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of non-contrast renal MR angiography for assessment of renal artery stenosis (RAS)up to study closure, estimated 3 monthsAccuracy of renal T-SLIP for assessing RAS severity in comparison to abdominal CTA. CTA is being used as the gold standard for comparison

Secondary

MeasureTime frameDescription
Safety assessment of non-contrast renal artery imagingmay be followed on average up to 3 months after closureSafety assessment of T-SLIP will be reported by documenting adverse clinical events (e.g. patient discomfort during scan)
Image qualityup to study closure, estimated 3 monthsMR angiography image quality will be determined in a blinded fashion by two independent readers. This will be reported separately.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026